NeuroSense Therapeutics CEO Provides Key Corporate Update Video View video here: https://youtu.be/KCT2wzOqmNo

NeuroSense Therapeutics

CEO Provides Key Corporate Update Video

video here: https://youtu.be/KCT2wzOqmNo

CAMBRIDGE, Mass., July 18,

2022 -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative

diseases, today released a corporate update video from its Founder and CEO Alon Ben-Noon. Video highlights include the following:

Amyotrophic Lateral Sclerosis

(ALS) Clinical Program for Lead Drug Candidate PrimeC

watch the video for more on NeuroSense's progress to date and an overview of upcoming catalysts and milestones: https://youtu.be/KCT2wzOqmNo

NeuroSense Therapeutics, Ltd.

is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative

diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS),

Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with

limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on

strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple

pathways associated with these diseases.

For additional information,

Forward-Looking Statements

This press release contains

"forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements

of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press

release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could,"

"estimate," "expect," "intend," "seek," "may," "might," "plan,"

"potential," "predict," "project," "target," "aim," "should," "will"

"would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these

words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties,

risks and assumptions that are difficult to predict and include statements regarding patent applications; the company's PrimeC development

program; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the timing of current

and future clinical trials; the nature, strategy and focus of the company and further updates with respect thereto; and the development

and commercial potential of any product candidates of the company. Further, certain forward-looking statements are based on assumptions

as to future events that may not prove to be accurate. Forward-looking statements contained in this announcement are made as of this date,

and NeuroSense Therapeutics Ltd. undertakes no duty to update such information except as required under applicable law.

For further information: Email:

info@neurosense-tx.com, Tel: +972 (0)9 799 6183